重症烧伤患者酶性清创:ICU与复苏期经验
该研究回顾性分析了29例复苏级别烧伤患者(TBSA≥15%)接受菠萝蛋白酶酶性清创的经验。2016至2020年间,酶性清创平均烧伤总面积从21.4%增至34.7%,实际清创面积从11.9%增至20.3% TBSA。66%患者在伤后24小时内清创,作者认为酶性清创在大面积烧伤中优势更明显。
要点
- 复苏级别烧伤(TBSA≥15%)患者可考虑酶性清创,但需团队和患者做好与手术清创同等准备。
- 环周肢体烧伤或计划单纯酶性清创者更可能在伤后24小时内开始酶性清创。
- 作者倡导先在较小烧伤中积累经验并建立本地路径,再用于大面积烧伤。
核心结论
- 酶性清创的优势在大面积烧伤中可能更明显,可在ICU病房内于入院当日完成全烧伤清创。
- 作者报告失血量显著减少、真皮保留改善、自体移植需求减少和去手术室次数减少。
研究设计与样本
- 回顾性病例系列,检索IBID数据库纳入29例成人复苏级别烧伤患者(TBSA≥15%,年龄>16岁)或烧伤后3级入院并接受酶性清创者。
- 记录人口学、TBSA、烧伤机制、吸入性损伤、清创时序、ICU和住院时间、血制品使用及自体移植需求。
主要发现
- 2016年6月至2020年6月,至少部分烧伤接受酶性清创患者的平均总烧伤面积从2016/17年的21.4%增至2019/20年的34.7%。
- 上述患者实际酶性清创面积从11.9% TBSA增至20.3% TBSA。
- 19例(66%)在伤后24小时内行酶性清创,另2例(7%)在伤后48小时内。
- 环周肢体烧伤(39% vs 9%)或计划单纯酶性清创(78% vs 28%)者更可能在伤后24小时内开始酶性清创。
- 计划联合酶性和手术清创者更可能在伤后48小时后开始酶性清创(75%)。
临床怎么用
- 对复苏级别烧伤患者,团队和患者需做好与传统手术清创同等的准备。
- 建议先在较小烧伤中积累酶性清创经验并建立稳健的本地路径,再尝试用于大面积烧伤。
- 环周肢体烧伤或计划单纯酶性清创者可考虑伤后24小时内开始酶性清创。
局限性
- 回顾性病例系列,样本量29例。
- 未寻求伦理批准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Much of the recent literature on bromelain based enzymatic debridement of burn injury has focused on its use in smaller burn injury and specialist areas such as the hands or genitals (Krieger et al., 2012; Schulz et al., 2017a,b,c,d). This is despite the original papers describing its use in larger burn injury (Rosenberg et al., 2004, 2014). The current EMA license for Nexobrid™ advises that it should not be used for burn injuries of more than 15% TBSA and should be used with caution in patients with pulmonary burn trauma and suspected pulmonary burn trauma. The original safety and efficacy trial of NexoBrid™ limited its use to 15% TBSA aliquots with concern regarding the effect of bromelain on coagulation. In a European consensus paper of experienced burns clinicians, now on its second iteration, 100% of respondents agreed that "up to 30% BSA can be treated by enzymatic debridement based on individual decision" (Hirche et al., 2017). Hofmaenner et al.'s recent study on the safety of enzymatic debridement in extensive burns larger than 15% provides some further evidence that "bromelain based enzymatic debridement can be carried out safely in large-area burns" (Hofmaenner et al., 2020) but the literature is scant in these larger debridement areas. In our centre we have been using enzymatic debridement for resuscitation level burn injury since 2016. We have gained significant learning in this time; this article aims to describe our current protocol for enzymatic debridement in this patient population and highlight specific learning points that might aid other centres in using enzymatic debridement for larger burn injury. METHOD: We performed a search of the IBID database to identify all adult patients who satisfied the inclusion criteria of resuscitation level burn injury (defined as total burn surface area (TBSA) ≥15% in patients aged >16 years), or level 3 admission following burn injury and who underwent Enzymatic Debridement. A case note review was completed, and details comprising patient demographics, TBSA, mechanism of burn, presence of inhalation injury, sequencing of debridement, length of ICU and hospital stay, blood product utilisation and the need for autografting were recorded. No ethical approval has been sought for this retrospective review. RESULTS: We identified 29 patients satisfying the inclusion criteria (Table 1). Between June 2016 and June 2020 the average total burn size of patients who had at least some of their burn treated by enzymatic debridement increased from 21.4% in 2016/17 to 34.7% in 2019/20. In these patients the actual area treated by enzymatic debridement also increased from 11.9% TBSA to 20.3% TBSA. 19 patients (66%) had enzymatic debridement performed within 24 h of injury, a further 2 patients (7%) within 48 h after injury. Patients were more likely to have enzymatic debridement commenced in the first 24 h after injury if they had circumferential limb injury (39% vs 9%) or were planned for enzyme only debridement (78% vs 28%). Those who were planned for combination enzyme and surgical debridement were more likely to have enzymatic debridement commenced after the first 48 h (75%). We have performed enzymatic debridement overnight on one occasion, for a patient who presented with circumferential limb injury and was determined to undergo urgent debridement. CONCLUSION: Much of the literature has described the use of enzymatic debridement in smaller burns, and specialist areas. However, it is our opinion that the advantages of enzymatic debridement appear to be greater in larger burns with a facility for whole burn excision on the day of admission in the ICU cubicle. We have demonstrated significantly reduced blood loss, improved dermal preservation, reduced need for autografting, and a reduction in the number of trips to theatre. We would advocate that both the team and the patient need to be as prepared as they would be for a traditional surgical excision. The early part of our learning curve for enzymatic debridement in resuscitation level injuries was steep, and we were able to build on experience from managing smaller injuries. We recommend any team wishing to using enzymatic debridement gain experience in the same way and develop robust local pathways prior to attempting use in larger burn injuries.
引用
- Bowers C, Randawa A, Sloan B, et al. Enzymatic debridement in critically injured burn patients - Our experience in the intensive care setting and during burn resuscitation. Burns. 2021. PMID: 34493422. doi:10.1016/j.burns.2021.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。